Document is current

Article History

Received: 11 July 2025

Accepted: 21 January 2026

First Online: 28 January 2026

Competing interests

: R. Sánchez Bayona reports advisory/consulting/speaker fees from Roche, AstraZeneca, Novartis, Lilly, Daiichi Sankyo, Pfizer, Eisai, GlaxoSmithKline, Reveal Genomics, and Gilead, travel expenses from Pfizer, AstraZeneca, Gilead, Novartis, and Roche. D. Generali reports Advisory role for Roche, Novartis, Pfizer; speaker honoraria from Roche, Lilly, Novartis, Pfizer, Menarini, AstraZeneca, Gilead; travel Grants from Roche; research funding (to the Uni) from Novartis. T. Pascual reports advisory and consulting fees or speaker honoraria from Novartis, Astra Zeneca, Lilly, Pfizer, Veracyte, Gilead, and Roche, and support for attending meetings and/or travel from Gilead. A. Gennari reports Research grants: Pharmanutra, AAA; advisory boards, activities as a speaker, travel grants, consultancy: Roche, Novartis, Pfizer, Eli Lilly, Daiichi Sankyo, AstraZeneca, MSD, Seagen, Gilead, Pierre Fabre, Eisai, Exact Sciences, Stemline. J. Cortés reports ARIAD Grant/Contract; AstraZeneca Grant/Contract, Other, Consulting; Baxalta GMBH/Servier Affaires Grant/Contract; Bayer Grant/Contract; Eisai Grant/ Contract, Travel, Other, honoraria; Guardant Health Grant/Contract; MSD Grant/Contract, Other, honoraria, consulting; Pfizer Grant/Contract, Travel, Other, honoraria, consulting; Puma Grant/Contract; Roche Grant/Contract, Travel, Other, honoraria, consulting; Piqur Grant/Contract; Novartis Travel, Other, honoraria; Celgene Other, consulting, honoraria; Samsung Other, honoraria; Daiichi Sankyo Travel, Other, honoraria, consulting; Eli Lilly Other, honoraria; Reveal Genomics Other, Consulting; Seagen Other, Consulting; Menarini Other, Consulting; Leuko Stock, Other, Consulting. N. Harbeck reports consulting fees from Gilead, Sandoz and Seagen; speaker honoraria from Amgen, AstraZeneca, Daiichi Sankyo, Gilead, Eli Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche and Seagen; honoraria for data safety monitoring board from Roche; and a leadership position at the West German Study Group (minority ownership). A. Prat reports advisory and consulting fees from AstraZeneca, Roche, Pfizer, Novartis, Daiichi Sankyo, Ona Therapeutics, and Peptomyc, lecture fees from AstraZeneca, Roche, Novartis, and Daiichi Sankyo, institutional financial interests from AstraZeneca, Novartis, Roche, and Daiichi Sankyo; stockholder and employee of Reveal Genomics; patents filed PCT/EP2016/080056, PCT/EP2022/ 086493, PCT/EP2023/060810, EP23382703, and EP23383369; editor of NPJ Breast Cancer journal. F. Schettini reports honoraria from Novartis, Gilead, Veracyte, Astra-Zeneca and Daiichy-Sankyo for educational events/materials, advisory fees from Pfizer, Astra-Zeneca, Daiichy-Sankyo and Veracyte, and travel expenses from Novartis, Astra-Zeneca, Gilead and Daiichy-Sankyo. The other authors have nothing to declare.